LinkedIn Profile

Access Nuclea Biotechnologies historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:nucleabiotechnologies 731424 Dec 3rd, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Dec 3rd, 2020 12:00PM Dec 3rd, 2020 12:00PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Dec 2nd, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Dec 2nd, 2020 02:21PM Dec 2nd, 2020 02:21PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Dec 1st, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Dec 1st, 2020 01:49PM Dec 1st, 2020 01:49PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 30th, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 29th, 2020 07:53PM Nov 30th, 2020 02:41PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 28th, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 28th, 2020 03:29PM Nov 28th, 2020 03:29PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 27th, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 27th, 2020 11:54AM Nov 27th, 2020 11:54AM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 26th, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 26th, 2020 12:52PM Nov 26th, 2020 12:52PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 25th, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 25th, 2020 06:25PM Nov 25th, 2020 06:25PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 24th, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 24th, 2020 01:43PM Nov 24th, 2020 01:43PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services
private:nucleabiotechnologies 731424 Nov 23rd, 2020 12:00AM Nuclea Biotechnologies 517 15.00 Open Biotechnology Nov 23rd, 2020 03:44PM Nov 23rd, 2020 03:44PM Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of novel biomarkers and antibodies that continue to fill our assay pipeline. In 2013, Nuclea acquired Oncogene Sciences ELISA products, including the HER2/neu IVD diagnostic kit, considered the gold standard in testing for metastatic breast cancer. Nuclea is also a leading innovator in mass spec testing. At our CLIA lab based in Cambridge Massachusetts, we offer a range of fully validated and reimbursable tests for proteins associated with cancer and other chronic diseases. Our Cambridge facility offers state-of-the-art mass spectrometry assays for serum or plasma proteins associated with diabetes and metabolic syndrome. Because of the unique biomarkers in an individual’s proteome, proteomic testing delivers a personalized, real-time snapshot of disease. Nuclea is at the forefront of proteomics. Whether providing an assay, test kit, or clinical lab service, Nuclea continues to set the standard for excellence, quality and innovation in this rapidly growing field. Open Open 100 Acorn Park Drive, 6th Floor Cambridge MA US 02140 Nuclea Biotechnologies Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.